The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole
Authors:
Open Access
- 4 March 2013
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (8) , 810-818
Abstract
Background Higher body mass index (BMI) is a recognised risk factor for gastro-oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting. Aim To assess the impact of BMI on baseline heartburn symptom severity and frequency and response to PPI therapy in patients with non-erosive GERD (NERD) or erosive oesophagitis (EO). Methods In post hoc analyses of phase 3 trial data, 621 NERD and 2692 EO patients were stratified by BMI (2). NERD patients received either dexlansoprazole MR 30 mg or placebo daily for 4 weeks. EO patients received either dexlansoprazole MR 60 mg or lansoprazole 30 mg for 8 weeks. Symptom frequency and severity were assessed at baseline and subsequently by daily diary. Results In both the NERD and EO cohorts, baseline heartburn severity increased with increasing BMI. The impact of PPI therapy on the reduction in heartburn symptom frequency and severity in both NERD and EO patients was similar across BMI categories. EO healing rates in patients treated with dexlansoprazole but not lansoprazole were higher in obese patients compared with those with a BMI 2. Differences between the PPIs were small. Conclusions The PPIs evaluated in this study reduced the frequency and severity of 24-h heartburn regardless of baseline BMI. In addition, because patients with higher BMI have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole (NERD and erosive oesophagitis) and possibly lansoprazole (erosive oesophagitis) treatment.Keywords
This publication has 36 references indexed in Scilit:
- Comparison of Clinical Characteristics of Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Versus Those Who Fully RespondedJournal of Neurogastroenterology and Motility, 2011
- Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazoleBMC Gastroenterology, 2011
- Increasing body weight enhances prevalence and proximal extent of reflux in GERD patients ‘on’ and ‘off’ PPI therapyNeurogastroenterology & Motility, 2011
- BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopyGut, 2010
- Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux diseaseAlimentary Pharmacology & Therapeutics, 2010
- Obesity and Gastroesophageal Reflux: Quantifying the Association Between Body Mass Index, Esophageal Acid Exposure, and Lower Esophageal Sphincter Status in a Large Series of Patients with Reflux SymptomsJournal of Gastrointestinal Surgery, 2009
- The Association Between Obesity and GERD: A Review of the Epidemiological EvidenceDigestive Diseases and Sciences, 2008
- Association of body mass index with heartburn, regurgitation and esophagitis: Results of the Progression of Gastroesophageal Reflux Disease studyJournal of Gastroenterology and Hepatology, 2007
- Obesity increases oesophageal acid exposureGut, 2006
- Predictors of treatment response in patients with non‐erosive reflux diseaseAlimentary Pharmacology & Therapeutics, 2006